Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001012975-25-000773
Filing Date
2025-11-14
Accepted
2025-11-14 16:30:04
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 29210
  Complete submission text file 0001012975-25-000773.txt   30908
Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund IX, L.P. (Filed by) CIK: 0001666306 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102
Business Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102 (206) 701-7914
Sana Biotechnology, Inc. (Subject) CIK: 0001770121 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-92124 | Film No.: 251487026
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)